오메가3 처방약 시장 : 기회, 성장 동인, 산업 동향 분석 및 예측(2024-2032년)

The Global Omega-3 Prescription Drugs Market was valued at approximately USD 1.4 billion. Projections indicate a growth rate of 8.2% CAGR from 2024 to 2032. These drugs, formulated with highly purified omega-3 fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are primarily used to treat or manage conditions such as cardiovascular diseases, metabolic disorders, and certain inflammatory or neurological issues.

The market growth is significantly driven by the rising prevalence of cardiovascular diseases. A report from the World Heart Federation (WHF) highlighted that the global deaths from cardiovascular disease (CVD) reached 20.5 million in 2021. CVD topped the list as the leading cause of death worldwide in 2021, with a staggering 80% of these fatalities occurring in low- and middle-income countries (LMICs). Such statistics emphasize the urgent demand for effective treatments, like omega-3 prescription drugs, to manage cardiovascular conditions and enhance global health outcomes.

Research and development (R&D) advancements are amplifying the therapeutic potential of omega-3 prescription drugs and broadening their applications. Innovations in purification and formulation technologies are yielding highly concentrated omega-3 preparations, boasting enhanced bioavailability and efficacy. These advancements aim to harness the full therapeutic benefits of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while curtailing potential side effects. Furthermore, ongoing research is delving into additional therapeutic avenues for omega-3 prescription drugs, venturing beyond cardiovascular health. Areas of exploration include neurological conditions, metabolic disorders, and inflammatory diseases, with clinical trials evaluating omega-3s for managing Alzheimer's disease, rheumatoid arthritis, and diabetes.

The Global Omega-3 Prescription Drugs Industry is classified based on drug type, application, distribution channel and region.

The market categorizes drug types into vascepa, lovaza, and others. Projections suggest the vascepa segment will hit USD 1.3 billion by 2032. Vascepa, a highly concentrated and refined formulation, boasts pure eicosapentaenoic acid (EPA). This high purity guarantees a potent dose of EPA, free from common contaminants in lesser purified omega-3 supplements, thereby amplifying its effectiveness. Clinical evidence underscores Vascepa's prowess: it's not only effective in curbing elevated triglyceride levels-a primary cardiovascular disease risk factor-but also significantly diminishes the risk of major cardiovascular events, as highlighted in studies like the REDUCE-IT trial.

The U.S. omega-3 prescription drugs market is on track to reach USD 1.1 billion by 2032. The U.S. Food and Drug Administration (FDA) enforces stringent oversight and approval processes for these drugs, ensuring they uphold high safety, efficacy, and quality standards. Such regulatory rigor bolsters consumer confidence, fueling market growth. Additionally, the surging incidence of diabetes plays a pivotal role in this market expansion. Data from the Public Health Agency of Canada reveals that in 2021, about 9.4% of the population-translating to 3.7 million individuals-were diagnosed with diabetes, with male prevalence at 10% and female at 8.7%.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Growing awareness of health benefits
    • 3.2.1.3 Advancements in research and development
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with omega-3 drugs
    • 3.2.2.2 Potential side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vascepa
• 5.3 Lovaza
• 5.4 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular diseases
• 6.3 Diabetes
• 6.4 Neurological disorders
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca plc
• 9.2 Amarin Corporation plc
• 9.3 Camber Pharmaceuticals, Inc.
• 9.4 Dr. Reddy's Laboratories Ltd.
• 9.5 GSK plc
• 9.6 Grupo Ferrer Internacional, S.A.
• 9.7 Hikma Pharmaceuticals PLC
• 9.8 Natco Pharma Limited
• 9.9 Pfizer Inc.
• 9.10 Viatris Inc.
• 9.11 Zydus Lifesciences Limited